Ajinomoto Aminoscience LLC Showcases New Commercial Opportunities of Recombinant Protein Technology
Published: Sep 08, 2010
Along with highlighting CorynexTM, the new whitepaper, entitled “Speeding and Simplifying Recombinant Protein Production,” also examines market drivers of recombinant protein production, challenges unique to each protein, benefits and drawbacks of expression systems (bacteria, yeast, and mammalian host cells), as well as key considerations and questions to ask when selecting a production process.
Recombinant protein technology provides a wealth of commercial opportunities. However, production is time-consuming, costly and subject to technical pitfalls. In addition, conventional microbe-based expression systems often use micro-organisms such as E. coli, pseudomonas and yeast, which require multiple purification steps, additional subsequent refolding and may contribute impurities. Traditionally, overcoming these challenges has meant refining or optimizing individual steps within the production process.
Ajinomoto’s CorynexTM Recombinant Protein Expression System uses a specially-developed gram-positive bacterium, Corynebacterium glutamicum. The expression system secretes correctly-folded, active proteins directly into the growth media with minimal host cell protein secretion and no endotoxins. By secreting active proteins directly into the growth media, Corynex eliminates the need for extensive downstream processing and additional refolding steps, which often result in 50% to 80% losses in target proteins.
In addition to developing the whitepaper, Ajinomoto has also created an educational video that uses computer-generated animation to illustrate protein expression in a way that’s never before been seen. The video provides an in-depth look at the expression and export of recombinant proteins from Corynebacterium glutamicum compared to E. coli and demonstrates how CorynexTM allows the recombinant protein to be readily purified directly from the fermentation broth.
To download a free copy of the whitepaper, “Speeding and Simplifying Recombinant Protein Production” and view the revolutionary new 3D animation of Ajinomoto’s CorynexTM Recombinant Protein Expression System, please visit www.corynex.com.
About Ajinomoto AminoScience, LLC
Ajinomoto is the leading supplier of pharmaceutical and research-grade amino acids in the US and throughout the world. Leveraging its unrivaled foundation of more than 50 years of experience identifying, refining, and marketing amino acids, Ajinomoto AminoScience, LLC (AAS) continues to innovate and set new industry standards for manufacturing and related services within the fermentation and expression fields. Building on its legacy, AAS has transitioned the same level of quality and performance into new core competencies in the areas of recombinant protein expression and peptide synthesis. These new processes enable pharmaceutical and bio-tech companies to develop high-quality products that were previously thought to be too complicated or expensive to produce. The CorynexTM Recombinant Protein Expression System is a streamlined, more efficient process to produce complex human proteins for pharmaceutical use using a specially-developed gram-positive bacterium, Corynebacterium glutamicum. The AjiPhase™ service enables the use of a single peptide synthesis methodology throughout therapeutic peptide development as peptide requirements increase. Ajinomoto AminoScience, LLC is a part of Ajinomoto USA Inc., a wholly-owned subsidiary of Ajinomoto Co., Inc. For more information on AAS and its products and services, please refer to http://www.ajiaminoscience.com/Default.aspx